uniQure (QURE) Projected to Post Earnings on Tuesday

uniQure (NASDAQ:QURE) will likely be releasing its Q1 2025 earnings data before the market opens on Tuesday, May 6th. Analysts expect uniQure to post earnings of ($1.07) per share and revenue of $5.93 million for the quarter.

uniQure Stock Performance

Shares of QURE stock opened at $14.77 on Friday. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18. The firm has a 50 day moving average of $12.15 and a two-hundred day moving average of $11.89. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a market capitalization of $809.04 million, a PE ratio of -2.98 and a beta of 0.10.

Wall Street Analyst Weigh In

Several research firms recently commented on QURE. Wells Fargo & Company lowered their target price on uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a research note on Friday, February 28th. StockNews.com upgraded shares of uniQure to a “sell” rating in a research note on Tuesday, March 11th. HC Wainwright reiterated a “buy” rating and set a $70.00 price target on shares of uniQure in a report on Monday, April 21st. Royal Bank of Canada reissued an “outperform” rating and issued a $24.00 price objective on shares of uniQure in a research report on Tuesday, January 21st. Finally, Chardan Capital began coverage on shares of uniQure in a research note on Tuesday, April 1st. They set a “buy” rating and a $38.00 target price for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, uniQure currently has an average rating of “Moderate Buy” and a consensus price target of $38.80.

Insider Buying and Selling at uniQure

In related news, CEO Matthew C. Kapusta sold 26,727 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $285,978.90. Following the completion of the sale, the chief executive officer now owns 571,188 shares in the company, valued at $6,111,711.60. This represents a 4.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Christian Klemt sold 14,341 shares of uniQure stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $153,448.70. Following the completion of the transaction, the chief financial officer now owns 152,372 shares in the company, valued at approximately $1,630,380.40. This represents a 8.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 90,830 shares of company stock worth $961,401 over the last 90 days. Corporate insiders own 4.74% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.